Abstract
Background
In the current era of the global increase in autoimmune and inflammatory disorders, predominantly rheumatoid arthritis (RA), there is mounting interest in developing advanced, safe, and patient-compliant treatment strategies. Phytoconstituents have gained more attention in recent years as budding complementary medicines for RA. Among them, 3-Acetyl-11-keto-β-boswellic acid (AKBA), derived from Boswellia serrata extract, is considered a promising phytoconstituent due to its anti-inflammatory and anti-arthritic potential. However, due to its poor solubility, low bioavailability (less than 10%), and poor permeability, its therapeutic potential is limited. Therefore, to overcome these issues, we have developed novel hyaluronic acid-surface-engineered lyotropic liquid crystalline nanoparticles encapsulating AKBA (HA-AKBA-LCNP) for cutaneous site-specific distribution and enhanced therapeutic effectiveness in RA.
Results
The quality-by-design-based optimized uncoated LCNP (N-AKBA-LCNP) and HA-AKBA-LCNP exhibited particle sizes below 150 nm and entrapment efficiency (%) close to 80%, making them suitable for cutaneous penetration and availability at the disease site. The cell viability studies in the RAW264.7 cell line revealed no cytotoxicity. Uncoated LCNP and HA-coated LCNP showed 1.37- and 2.19-fold improved cell uptake, respectively, compared to free form. An in vitro study also demonstrated a significant anti-inflammatory effect of the developed LCNP system against RAW264.7 cells, characterized by a decrease in pro-inflammatory cytokines and an increase in anti-inflammatory cytokines. The N-AKBA-LCNP and HA-AKBA-LCNP embedded gels demonstrated improved permeation (2.34- and 2.40-fold, respectively) and improved retention (4.98- and 6.73-fold, respectively) of AKBA in the viable dermal layers compared to the free AKBA gel. In vivo investigation revealed a significant depletion in paw edema (p < 0.0001), inflammatory cytokine levels (p < 0.0001), and CD44 expression (p < 0.001) by HA-AKBA-LCNP in the Freund’s Complete Adjuvant-induced rat model of arthritis.
Conclusion
The study results exhibited the promising potential of HA-functionalized AKBA-loaded LCNP as a targeted, biocompatible, and efficient dermal delivery approach for an enhanced treatment strategy to counter the RA disease burden.
Download the full article as PDF here Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-β-boswellic acid in rheumatoid arthritis treatment
or continue reading here
Materials
AKBA (> 94% purity) was purchased from Gurjar Phytochem Pvt. Ltd. (Madhya Pradesh, India). HA (Molecular weight ≈ 10,000 Da) was obtained from Meteoric Biopharmaceuticals Pvt. Ltd. LPS (rough strains) from Escherichia coli (Rd mutant), 4’, 6-diamidine-2’-phenylindole dihydrochloride (DAPI), 2’, 7’-dichlorofluorescein (DCF), and FCA were purchased from Sigma Aldrich. Stearyl amine and Coumarin-6 were procured from Tokyo Chemical Industry Co., Ltd. Deuterated dimethyl sulphoxide (d-DMSO) and deuterated water (D20) were bought from SRL Pvt. Ltd, (Mumbai, India). Hydrogen peroxide solution 30% was purchased from Rankem chemicals. Dulbecco’s Modified Eagle Medium (DMEM) with high glucose was obtained from Gibco (New York, USA). Fetal bovine serum (FBS), RDP-Trio reagent, mannitol, Phosphate-Buffer Saline (PBS) pH 7.4, dialysis membrane, chloroform, diethyl pyrocarbonate-treated water, and isopropanol were acquired from Himedia (Mumbai, India). 3-(4,5-Dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT) was procured from Invitrogen (Thermo Fisher Scientific). iScript cDNA synthesis kit and iTaq™ Universal SYBR® Green Supermix were acquired from BIO-RAD. Tumor necrosis factor-alpha (TNF-α), Interleukin (IL)−10, and CD44 Primers are procured from Integrated DNA Technologies. Milli-Q water (ultrapure deionized water) was collected from an in-house Milli-Q water purification system, Millipore (USA).
Priya, S., Verma, V., Roy, A. et al. Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-β-boswellic acid in rheumatoid arthritis treatment. J Nanobiotechnol 23, 725 (2025). https://doi.org/10.1186/s12951-025-03846-5
Read also our introduction article on mannitol here:

















































